X4 Pharmaceuticals opened lower at $3.33, compared with its previous close of $3.36. In the last trading session, the stock traded between $3.19 and $3.41. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in X4 Pharmaceuticals is now worth
$ 2.26
resulting in a loss of
$ 97.74 (97.74%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.08 (-2.23%)
Day High
$3.41
Day Low
$3.19
Day Open
$3.33
Prev Close
$3.36
Volume
3,85,021
1W Return
2.82%
1M Return
13.08%
3M Return
-17.85%
6M Return
-19.88%
1Y Return
-12.17%
Fundamentals
Market Cap ($ Mn)
326
PE Ratio
202.50
PB Ratio
2.50
PEG Ratio
-
ROE
-133.34%
ROCE
-53.11%
EPS (TTM)
$-0.17
Investment Returns
1 Week
2.82%
1 Month
13.08%
3 Months
-17.85%
6 Months
-19.88%
9 Months
-10.98%
Financials
Quarterly
All values in $ Mn
1.4
Dec 24
28.8
Mar 25
2.0
Jun 25
1.8
Sep 25
2.6
Dec 25
8.8
Jun 26
Updates
2Oct
X4 Pharmaceuticals grants 80,000 stock options to new hires
Issued 80,000 inducement stock options to new employees. Exercise price set at $2.90 per share, matching Sept 30 close. Options vest over four years with a 25% cliff after 12 months. Grants made under Nasdaq Listing Rule 5635(c)(4) via 2019 Inducement Plan.
28 days ago
8Sep
X4 Pharma secures FDA nod for smaller chronic neutropenia trial
FDA agrees to reduce 4WARD Phase 3 trial sample size from 176 to 126 participants. Company maintains adequate statistical power for co-primary endpoints on infection rate and ANC response. Enrollment completion targeted for year-end 2026 with topline data expected in H1 2028. Mavorixafor targets estimated 15,000 patients with chronic neutropenia in the US.
1mo ago
2Sep
X4 Pharmaceuticals grants 50,000 stock options to new hires
X4 Pharmaceuticals granted options for 50,000 shares to new employees. Exercise price set at $4.04 per share, equal to closing price on August 31, 2026. Awards vest over four years, with 25% vesting after the first year. Grants comply with Nasdaq Listing Rule 5635(c)(4) for inducement awards.
1mo ago
7Aug
X4 Pharmaceuticals posts $8.8M Q2 revenue, secures EU drug approval
X4 Pharmaceuticals delivered strong Q2 2026 results with $8.8 million in revenue, driven by US product sales and Norgine license fees. The company also achieved European regulatory approval for XOLREMDI, enhancing its commercial potential in rare hematology diseases.
2mo ago
4Aug
X4 Pharmaceuticals grants 12,000 stock options to new hires
X4 Pharmaceuticals granted 12,000 stock options to new hires at $3.98 per share, effective July 31, 2026. The awards vest over four years and comply with Nasdaq Listing Rule 5635(c)(4).
2mo ago
10Jul
Wells Fargo initiates coverage on X4 Pharmaceuticals with Overweight rating
Wells Fargo analyst Derek Archila initiated coverage on X4 Pharmaceuticals with an Overweight rating and a price target of $11, indicating a positive outlook for the stock.
